Presenilin immunoreactivity in Alzheimer's disease

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The role of presenilin (PS) mutations in familial Alzheimer's disease (AD) may be as a toxic gain of function, but in sporadic disease their contribution is more difficult to understand. In this study, we investigated PS proteins in sporadic AD by comparing the immunocytochemical profiles in sporadic AD with control brains using a quantitative immunocytochemical approach to both the N- and C-terminals of PS1 and PS2. Ten patients with pathologically proven AD (using modified Consortium to Establish a Registry for Alzheimer's Disease [CERAD] criteria) and 10 controls were age- and sex-matched. The immunocytochemical primary antibodies were affinity-purified goat polyclonal antibodies and the secondary antibodies were biotinylated donkey anti-goat to the N- and C-terminal of both PS1 and PS2. The number of PS-containing neurones was quantified manually and without the knowledge of the diagnosis. We found no significant differences in the number of PS1- and PS2-containing neurones in three anatomical regions for both N- and C-terminals between AD and controls. Our findings argue in favour of functional changes in PS molecules contributing to the pathogenesis of AD and are consistent with the hypothesis of dysfunction of the entire γ-secretase complex, of which PS proteins are a constituent.

Original languageEnglish
Pages (from-to)700-706
Number of pages7
JournalEuropean Journal of Neurology
Volume12
Issue number9
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Presenilins
Alzheimer Disease
Goats
Neurons
Amyloid Precursor Protein Secretases
Antibody Affinity
Antibodies
Equidae
Poisons
Registries
Proteins
Mutation
Brain

Cite this

@article{3c0aad96afee41bda63398cb9f9fe7bb,
title = "Presenilin immunoreactivity in Alzheimer's disease",
abstract = "The role of presenilin (PS) mutations in familial Alzheimer's disease (AD) may be as a toxic gain of function, but in sporadic disease their contribution is more difficult to understand. In this study, we investigated PS proteins in sporadic AD by comparing the immunocytochemical profiles in sporadic AD with control brains using a quantitative immunocytochemical approach to both the N- and C-terminals of PS1 and PS2. Ten patients with pathologically proven AD (using modified Consortium to Establish a Registry for Alzheimer's Disease [CERAD] criteria) and 10 controls were age- and sex-matched. The immunocytochemical primary antibodies were affinity-purified goat polyclonal antibodies and the secondary antibodies were biotinylated donkey anti-goat to the N- and C-terminal of both PS1 and PS2. The number of PS-containing neurones was quantified manually and without the knowledge of the diagnosis. We found no significant differences in the number of PS1- and PS2-containing neurones in three anatomical regions for both N- and C-terminals between AD and controls. Our findings argue in favour of functional changes in PS molecules contributing to the pathogenesis of AD and are consistent with the hypothesis of dysfunction of the entire γ-secretase complex, of which PS proteins are a constituent.",
keywords = "γ-secretase, Alzheimer's disease, Dementia, Presenilin 1 and 2",
author = "Panegyres, {P. K.} and K. Toufexis",
year = "2005",
month = "9",
doi = "10.1111/j.1468-1331.2005.01050.x",
language = "English",
volume = "12",
pages = "700--706",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "John Wiley & Sons",
number = "9",

}

Presenilin immunoreactivity in Alzheimer's disease. / Panegyres, P. K.; Toufexis, K.

In: European Journal of Neurology, Vol. 12, No. 9, 09.2005, p. 700-706.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Presenilin immunoreactivity in Alzheimer's disease

AU - Panegyres, P. K.

AU - Toufexis, K.

PY - 2005/9

Y1 - 2005/9

N2 - The role of presenilin (PS) mutations in familial Alzheimer's disease (AD) may be as a toxic gain of function, but in sporadic disease their contribution is more difficult to understand. In this study, we investigated PS proteins in sporadic AD by comparing the immunocytochemical profiles in sporadic AD with control brains using a quantitative immunocytochemical approach to both the N- and C-terminals of PS1 and PS2. Ten patients with pathologically proven AD (using modified Consortium to Establish a Registry for Alzheimer's Disease [CERAD] criteria) and 10 controls were age- and sex-matched. The immunocytochemical primary antibodies were affinity-purified goat polyclonal antibodies and the secondary antibodies were biotinylated donkey anti-goat to the N- and C-terminal of both PS1 and PS2. The number of PS-containing neurones was quantified manually and without the knowledge of the diagnosis. We found no significant differences in the number of PS1- and PS2-containing neurones in three anatomical regions for both N- and C-terminals between AD and controls. Our findings argue in favour of functional changes in PS molecules contributing to the pathogenesis of AD and are consistent with the hypothesis of dysfunction of the entire γ-secretase complex, of which PS proteins are a constituent.

AB - The role of presenilin (PS) mutations in familial Alzheimer's disease (AD) may be as a toxic gain of function, but in sporadic disease their contribution is more difficult to understand. In this study, we investigated PS proteins in sporadic AD by comparing the immunocytochemical profiles in sporadic AD with control brains using a quantitative immunocytochemical approach to both the N- and C-terminals of PS1 and PS2. Ten patients with pathologically proven AD (using modified Consortium to Establish a Registry for Alzheimer's Disease [CERAD] criteria) and 10 controls were age- and sex-matched. The immunocytochemical primary antibodies were affinity-purified goat polyclonal antibodies and the secondary antibodies were biotinylated donkey anti-goat to the N- and C-terminal of both PS1 and PS2. The number of PS-containing neurones was quantified manually and without the knowledge of the diagnosis. We found no significant differences in the number of PS1- and PS2-containing neurones in three anatomical regions for both N- and C-terminals between AD and controls. Our findings argue in favour of functional changes in PS molecules contributing to the pathogenesis of AD and are consistent with the hypothesis of dysfunction of the entire γ-secretase complex, of which PS proteins are a constituent.

KW - γ-secretase

KW - Alzheimer's disease

KW - Dementia

KW - Presenilin 1 and 2

UR - http://www.scopus.com/inward/record.url?scp=24744459424&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2005.01050.x

DO - 10.1111/j.1468-1331.2005.01050.x

M3 - Article

VL - 12

SP - 700

EP - 706

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 9

ER -